Malignancy risk in adults with growth hormone deficiency undergoing long-term treatment with biosimilar somatropin (Omnitrope(®)): data from the PATRO Adults study

BACKGROUND: To assess the safety (particularly the occurrence of malignancies) of growth hormone (GH) replacement (Omnitrope(®)) in adults with GH deficiency, using data from the ongoing PATRO Adults post-marketing surveillance study. METHODS: PATRO Adults is being conducted in hospitals and special...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Ther Adv Endocrinol Metab
Main Authors: Beck-Peccoz, Paolo, Höybye, Charlotte, Murray, Robert D, Simsek, Suat, Zabransky, Markus, Zouater, Hichem, Stalla, Günter
Formato: Artigo
Idioma:Inglês
Publicado: SAGE Publications 2020
Assuntos:
Original Research
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC7491215/
https://ncbi.nlm.nih.gov/pubmed/32973992
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/2042018820943377
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares